IPF
MCID: IDP011
MIFTS: 59

Idiopathic Interstitial Pneumonia (IPF)

Categories: Respiratory diseases

Aliases & Classifications for Idiopathic Interstitial Pneumonia

MalaCards integrated aliases for Idiopathic Interstitial Pneumonia:

Name: Idiopathic Interstitial Pneumonia 12 15
Idiopathic Interstitial Pneumonias 37 73
Pulmonary Fibrosis 44 73
Idiopathic Interstitial Pneumonia, Not Otherwise Specified 73
Diffuse Idiopathic Pulmonary Fibrosis 12
Idiopathic Fibrosing Alveolitis 12
Hamman-Rich Syndrome 73
Ipf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2797
MeSH 44 D011658
SNOMED-CT 68 45157009
KEGG 37 H01716

Summaries for Idiopathic Interstitial Pneumonia

Disease Ontology : 12 A pneumonia located in the lung parenchyma of unknown cause.

MalaCards based summary : Idiopathic Interstitial Pneumonia, also known as idiopathic interstitial pneumonias, is related to nonspecific interstitial pneumonia and desquamative interstitial pneumonia, and has symptoms including hemoptysis, snoring and coughing. An important gene associated with Idiopathic Interstitial Pneumonia is MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Bosentan and Pirfenidone have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and testes, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 76 Idiopathic interstitial pneumonia (IIP), or noninfectious pneumonia are a class of diffuse lung... more...

Related Diseases for Idiopathic Interstitial Pneumonia

Diseases related to Idiopathic Interstitial Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 407)
# Related Disease Score Top Affiliating Genes
1 nonspecific interstitial pneumonia 33.5 CCL2 IFNG IL13 SFTPC
2 desquamative interstitial pneumonia 33.1 MUC5B SFTPC
3 acute interstitial pneumonia 32.2 SFTPA1 SFTPA2 SFTPD
4 interstitial lung disease 32.0 CCL2 CXCL8 EDN1 IFNG IL4 MUC5B
5 pneumonia 31.0 CCL2 CXCL8 ELANE IL13 MUC5B SFTPC
6 pulmonary fibrosis, idiopathic 31.0 CCL2 CCN2 CXCL8 EDN1 ELANE IFNG
7 extrinsic allergic alveolitis 30.7 CCL2 CXCL8 SFTPD
8 silicosis 30.3 CCL2 CXCL8 SFTPD TGFB1
9 pulmonary sarcoidosis 30.3 CCL2 ICAM1 IFNG SFTPD
10 sarcoidosis 1 30.2 CCL2 ICAM1 IFNG IL13
11 pneumoconiosis 30.2 CCL2 CXCL8 MUC5B TGFB1
12 connective tissue disease 30.2 CCN2 EDN1 IFNG SFTPD TLR9
13 arthritis 30.2 CCL2 CXCL8 IFNG TGFB1
14 respiratory failure 30.1 CXCL8 ELANE SFTPC SFTPD
15 acute respiratory distress syndrome 30.1 CXCL8 ELANE SFTPC SFTPD
16 allergic hypersensitivity disease 30.1 IFNG IL13 IL4 TLR9
17 pulmonary alveolar proteinosis 30.0 CCL2 SFTPC SFTPD
18 colitis 30.0 CXCL8 IFNG IL4 TLR9
19 pulmonary emphysema 30.0 ELANE SFTPC SFTPD
20 severe acute respiratory syndrome 29.9 CCL2 CXCL8 IFNG
21 glomerulonephritis 29.8 CCL2 ICAM1 TGFB1 TLR9
22 sleep apnea 29.8 CXCL8 EDN1 ICAM1
23 viral infectious disease 29.8 CXCL8 CXCR4 IFNG IL4 TLR9
24 schistosomiasis 29.8 IFNG IL13 IL4
25 mycoplasma pneumoniae pneumonia 29.8 IFNG IL13 IL4
26 bronchiolitis 29.8 CXCL8 IFNG IL13 IL4 MUC5B TLR9
27 vascular disease 29.8 CCL2 EDN1 ELANE SERPINE1 VEGFA
28 rapidly progressive glomerulonephritis 29.8 ELANE ICAM1 TGFB1
29 pulmonary eosinophilia 29.8 IL13 IL4 SFTPD
30 esophagitis 29.7 CXCL8 IL13 TGFB1
31 dermatitis 29.7 IFNG IL13 IL4 TLR9
32 collagen disease 29.7 CCN2 EDN1 TLR9
33 otitis media 29.7 CXCL8 IL4 MUC5B
34 autoimmune disease 29.6 CCL2 IFNG IL4 TLR9
35 pulmonary disease, chronic obstructive 29.6 CCL2 CXCL8 ELANE IL13 SFTPD TGFB1
36 pulmonary fibrosis 29.6 CCL2 CCN2 EDN1 IL13 MUC5B SFTPA1
37 systemic scleroderma 29.6 CCN2 EDN1 IFNG SFTPD TGFB1 TLR9
38 pulmonary tuberculosis 29.6 IFNG IL4 TLR9
39 allergic asthma 29.6 IFNG IL13 IL4
40 contact dermatitis 29.5 CXCL8 ICAM1 IFNG IL4
41 adult respiratory distress syndrome 29.5 CXCL8 ELANE SERPINE1 SFTPC
42 kidney disease 29.5 CCL2 CCN2 EDN1 SERPINE1 TGFB1
43 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.5 CXCR4 IFNG IL4
44 pleurisy 29.5 CCL2 CXCL8 ICAM1 IFNG
45 lung disease 29.4 CCL2 CXCL8 EDN1 ELANE IL13 MUC5B
46 rheumatoid arthritis 29.4 CCL2 CXCL8 ICAM1 IFNG IL4 TGFB1
47 psoriasis 29.4 CCL2 CXCL8 ICAM1 IFNG IL13 IL4
48 arteries, anomalies of 29.3 CCL2 EDN1 ICAM1 SERPINE1 TLR9 VEGFA
49 systemic lupus erythematosus 29.1 CCL2 CXCL8 ELANE ICAM1 IFNG IL4
50 asthma 28.9 CCL2 CXCL8 CXCR4 EDN1 ELANE ICAM1

Comorbidity relations with Idiopathic Interstitial Pneumonia via Phenotypic Disease Network (PDN): (show all 22)


Acute Cystitis Aortic Valve Disease 1
Bronchiectasis Bronchitis
Bronchopneumonia Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Mitral Valve Disease Osteoporosis
Postinflammatory Pulmonary Fibrosis Protein-Energy Malnutrition
Pulmonary Hypertension, Primary, 1 Respiratory Failure
Rheumatoid Arthritis Rheumatoid Lung Disease

Graphical network of the top 20 diseases related to Idiopathic Interstitial Pneumonia:



Diseases related to Idiopathic Interstitial Pneumonia

Symptoms & Phenotypes for Idiopathic Interstitial Pneumonia

UMLS symptoms related to Idiopathic Interstitial Pneumonia:


hemoptysis, snoring, coughing

MGI Mouse Phenotypes related to Idiopathic Interstitial Pneumonia:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 CCN2 CXCR4 EDN1 ELANE GREM1 ICAM1
2 growth/size/body region MP:0005378 10.32 CCN2 CXCR4 EDN1 GREM1 ICAM1 IFNG
3 cellular MP:0005384 10.28 CCN2 CXCR4 GREM1 ICAM1 IFNG IL13
4 immune system MP:0005387 10.28 CCL2 CXCR4 ELANE ICAM1 IFNG IL13
5 hematopoietic system MP:0005397 10.27 CXCR4 ELANE ICAM1 IFNG IL13 IL4
6 mortality/aging MP:0010768 10.25 CCN2 CXCR4 EDN1 ELANE GREM1 ICAM1
7 digestive/alimentary MP:0005381 10.21 CCN2 CXCR4 EDN1 ICAM1 IFNG IL13
8 endocrine/exocrine gland MP:0005379 10.15 CCN2 CXCR4 EDN1 ICAM1 IFNG IL13
9 craniofacial MP:0005382 10.07 CCN2 CXCR4 EDN1 IFNG IL4 TGFB1
10 integument MP:0010771 10.02 CCN2 CXCR4 ICAM1 IFNG IL13 IL4
11 neoplasm MP:0002006 9.86 CXCR4 ELANE ICAM1 IFNG SERPINE1 SFTPC
12 renal/urinary system MP:0005367 9.81 CXCR4 EDN1 GREM1 IFNG IL4 SERPINE1
13 respiratory system MP:0005388 9.77 CCN2 CXCR4 GREM1 IFNG IL13 IL4
14 skeleton MP:0005390 9.28 CCN2 CXCR4 EDN1 GREM1 IFNG IL13

Drugs & Therapeutics for Idiopathic Interstitial Pneumonia

Drugs for Idiopathic Interstitial Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 3,Phase 2 147536-97-8 104865
2
Pirfenidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53179-13-8 40632
3
Nintedanib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 656247-17-5 56843413
4
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
5 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1
6 Sildenafil Citrate Phase 4,Phase 3,Phase 2 171599-83-0
7 Citrate Phase 4,Phase 3,Phase 2,Phase 1
8 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2
9 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2
10 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Endothelin Receptor Antagonists Phase 4,Phase 3,Phase 2
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
19
Iloprost Approved, Investigational Phase 2, Phase 3 78919-13-8 6443959
20
Acetylcysteine Approved, Investigational Phase 3,Phase 2,Phase 1 616-91-1 12035
21
Azathioprine Approved Phase 3,Phase 1,Phase 2,Not Applicable 446-86-6 2265
22
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
23
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 6055-19-2, 50-18-0 2907
24
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
25
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
26
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
27
Methylprednisolone hemisuccinate Approved Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
28
Mycophenolic acid Approved Phase 3 24280-93-1 446541
29
rituximab Approved Phase 3,Phase 2,Phase 1,Not Applicable 174722-31-7 10201696
30
Lenograstim Approved, Investigational Phase 3,Phase 1,Phase 2 135968-09-1
31
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
32
Angiotensin II Approved, Investigational Phase 2, Phase 3,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
33
Losartan Approved Phase 2, Phase 3,Not Applicable 114798-26-4 3961
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
35
Sulfamethoxazole Approved Phase 3 723-46-6 5329
36
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
37
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
38
Ambrisentan Approved, Investigational Phase 3 177036-94-1 6918493
39
Warfarin Approved Phase 3 81-81-2 6691 54678486
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
41
Prednisolone hemisuccinate Experimental Phase 3,Phase 1,Phase 2,Not Applicable 2920-86-7
42 Anti-Bacterial Agents Phase 3,Phase 2,Not Applicable
43 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Platelet Aggregation Inhibitors Phase 2, Phase 3
45 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
46 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
47 Anticoagulants Phase 3,Not Applicable
48 Antiviral Agents Phase 3,Phase 2,Phase 1
49 Free Radical Scavengers Phase 3,Phase 2,Phase 1
50 Antioxidants Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 345)
# Name Status NCT ID Phase Drugs
1 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
2 Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study Unknown status NCT00637065 Phase 4 Bosentan;Placebo
3 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
4 Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT02598193 Phase 4 Nintedanib;Pirfenidone
5 Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment Completed NCT02788474 Phase 4 nintedanib;placebo
6 Digital Auscultation Test - IPF Data Collection Completed NCT03503188 Phase 4
7 Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF Completed NCT02579603 Phase 4 Nintedanib;Pirfenidone
8 A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination Completed NCT02606877 Phase 4 nintedanib;pirfenidone
9 Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF) Recruiting NCT03717012 Phase 4 Nintedanib
10 68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis Terminated NCT01321996 Phase 4
11 Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil Withdrawn NCT00625079 Phase 4 sildenafil
12 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan Withdrawn NCT00625469 Phase 4 bosentan
13 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
14 Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis Unknown status NCT00439543 Phase 2, Phase 3 Iloprost inhalation
15 Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00600028 Phase 3 Thalidomide;Placebo
16 Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 Completed NCT00631475 Phase 3 Bosentan
17 Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis Completed NCT02739165 Phase 3 ART-123;Placebo
18 Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT01366209 Phase 3 Pirfenidone;Placebo
19 Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment Completed NCT02802345 Phase 3 Nintedanib;Placebo;Sildenafil
20 Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00071461 Phase 2, Phase 3 bosentan;Placebo
21 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00287716 Phase 3 Pirfenidone;Placebo
22 Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00287729 Phase 3 Pirfenidone;Placebo
23 BUILD 3: Bosentan Use in Interstitial Lung Disease Completed NCT00391443 Phase 3 Bosentan;Placebo
24 Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study Completed NCT00131274 Phase 2, Phase 3 Imatinib Mesylate (Gleevec)
25 Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT01979952 Phase 3 Matching Placebo;Nintedanib
26 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis Completed NCT00517933 Phase 3 Sildenafil Citrate
27 Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00662038 Phase 3 pirfenidone
28 A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00047645 Phase 3 Interferon-gamma 1b
29 Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00639496 Phase 3 n-acetylcysteine;placebo
30 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients Completed NCT01335464 Phase 3 placebo;BIBF 1120
31 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II Completed NCT01335477 Phase 3 placebo;BIBF 1120
32 Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization Completed NCT02584816 Phase 3
33 Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Completed NCT00650091 Phase 3 N-acetylcysteine (NAC);Placebo
34 A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients Completed NCT01014442 Phase 3 mycophenolate mofetil
35 A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis Completed NCT02597933 Phase 3 Nintedanib;Placebo
36 Rituximab in Rheumatoid Arthritis Lung Disease Completed NCT00578565 Phase 3 Rituximab
37 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
38 EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection Completed NCT00105183 Phase 3
39 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
40 A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard Medical Treatment Recruiting NCT03733444 Phase 3 GLPG1690;Placebo
41 A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard Medical Treatment Recruiting NCT03711162 Phase 3 GLPG1690;Placebo
42 Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Recruiting NCT02460588 Phase 3 Cyclophosphamide;Placebo;Corticosteroid (prednisolone)
43 Nebulized Fentanyl in Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis and Chronic Dyspnea Recruiting NCT03018756 Phase 3 Fentanyl Citrate;Placebo
44 CleanUP IPF for the Pulmonary Trials Cooperative Recruiting NCT02759120 Phase 3 Antimicrobial therapy: Co-trimoxazole or Doxycycline
45 Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). Active, not recruiting NCT03208933 Phase 3 Pirfenidone
46 Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis Active, not recruiting NCT01619085 Phase 3 BIBF 1120
47 Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis Not yet recruiting NCT03068234 Phase 2, Phase 3 Pirfenidone;Placebo oral capsule;Steroids
48 Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole Terminated NCT01777737 Phase 3 Cotrimoxazole;Placebo
49 Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Terminated NCT00981747 Phase 2, Phase 3 Sildenafil;Losartan;Sildenafil and Losartan;Placebo Oral Tablet
50 ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis Terminated NCT00879229 Phase 3 Ambrisentan;Placebo

Search NIH Clinical Center for Idiopathic Interstitial Pneumonia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: pulmonary fibrosis

Genetic Tests for Idiopathic Interstitial Pneumonia

Anatomical Context for Idiopathic Interstitial Pneumonia

MalaCards organs/tissues related to Idiopathic Interstitial Pneumonia:

41
Lung, Bone, Testes, Bone Marrow, Kidney, Thyroid, Skeletal Muscle

The Foundational Model of Anatomy Ontology organs/tissues related to Idiopathic Interstitial Pneumonia:

19
The Lung Parenchyma Of Unknown Cause

Publications for Idiopathic Interstitial Pneumonia

Articles related to Idiopathic Interstitial Pneumonia:

(show top 50) (show all 292)
# Title Authors Year
1
A Serological Biomarker of Versican Degradation is Associated with Mortality Following Acute Exacerbations of Idiopathic Interstitial Pneumonia. ( 29728109 )
2018
2
Idiopathic Interstitial Pneumonia as a Possible Cause of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Report. ( 29901014 )
2018
3
Cyclophosphamide in steroid refractory unclassifiable idiopathic interstitial pneumonia and interstitial pneumonia with autoimmune features (IPAF). ( 29496758 )
2018
4
Cardiorespiratory adaptation in a 6-minute walk test by fibrotic idiopathic interstitial pneumonia patients who did or did not respond to pulmonary rehabilitation. ( 29904044 )
2018
5
Effects of pulmonary rehabilitation on daily life physical activity of fibrotic idiopathic interstitial pneumonia patients. ( 29900176 )
2018
6
Proposed method of histological separation between connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonias. ( 30395623 )
2018
7
Secondary pulmonary alveolar proteinosis predominant in the transplanted lung in patients with idiopathic interstitial pneumonia: an autopsy case. ( 29997992 )
2018
8
Diagnostic value of KL-6 in idiopathic interstitial pneumonia. ( 30233844 )
2018
9
Clinical profile of unclassifiable interstitial lung disease: Comparison with chronic fibrosing idiopathic interstitial pneumonias. ( 28758849 )
2018
10
Prevalence of Myositis-Specific Antibodies in Idiopathic Interstitial Pneumonias. ( 29532165 )
2018
11
Pathology and radiology correlation of idiopathic interstitial pneumonias. ( 29180253 )
2018
12
Unclassifiable idiopathic interstitial pneumonias: A never-ending story? ( 29325674 )
2018
13
Is idiopathic PPFE an established subset of idiopathic interstitial pneumonias? ( 29325678 )
2018
14
Clinico-radio-pathological characteristics of unclassifiable idiopathic interstitial pneumonias. ( 29325680 )
2018
15
The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias. ( 29434143 )
2018
16
Distinct Profiles of CD163-Positive Macrophages in Idiopathic Interstitial Pneumonias. ( 29507864 )
2018
17
Corticosteroids in acute exacerbations of idiopathic interstitial pneumonias: Time to debate - Reply. ( 29527756 )
2018
18
Corticosteroids in acute exacerbations of idiopathic interstitial pneumonias: Time to debate. ( 29527763 )
2018
19
Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias. ( 29928060 )
2018
20
Update on Rare Idiopathic Interstitial Pneumonias and Rare Histologic Patterns. ( 30141991 )
2018
21
Continuous Neuromuscular Blockade and Mortality in Subjects With Exacerbation of Idiopathic Interstitial Pneumonias. ( 30154126 )
2018
22
Idiopathic interstitial pneumonias: review of the latest American Thoracic Society/European Respiratory Society classification. ( 30369660 )
2018
23
Classification of idiopathic interstitial pneumonias. ( 30369675 )
2018
24
Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year. ( 28300570 )
2017
25
Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia. ( 29229096 )
2017
26
Volume doubling time of lung cancer detected in idiopathic interstitial pneumonia: comparison with that in chronic obstructive pulmonary disease. ( 29038933 )
2017
27
Respiratory bronchiolitis-associated interstitial lung disease - an unexpected form of idiopathic interstitial pneumonia in a young male. ( 28523329 )
2017
28
Occupational and Environmental Risk Factors for Chronic Fibrosing idiopathic Interstitial Pneumonia in South Korea. ( 28938261 )
2017
29
Impact of lymphocyte differential counta88>a8815% in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia. ( 28427425 )
2017
30
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. ( 28838377 )
2017
31
Baseline serum syndecan-4 predicts prognosis after the onset of acute exacerbation of idiopathic interstitial pneumonia. ( 28467516 )
2017
32
Successful Treatment of Rapidly Progressive Unclassifiable Idiopathic Interstitial Pneumonia with Anti-Melanoma Differentiation-Associated Gene-5 Antibody by Intensive Immunosuppressive Therapy. ( 29269659 )
2017
33
Serial changes and prognostic implications of CT findings in combined pulmonary fibrosis and emphysema: comparison with fibrotic idiopathic interstitial pneumonias alone. ( 27565631 )
2017
34
A new era in idiopathic interstitial pneumonias: Epilogue to a review series. ( 27782346 )
2017
35
Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody. ( 28230086 )
2017
36
Leukocytapheresis for the treatment of acute exacerbation of idiopathic interstitial pneumonias: a pilot study. ( 28373606 )
2017
37
Low-Dose Morphine for Dyspnea in Terminally Ill Patients with Idiopathic Interstitial Pneumonias. ( 28437202 )
2017
38
High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. ( 28508494 )
2017
39
The importance of subpleural fibrosis in the prognosis of patients with idiopathic interstitial pneumonias. ( 28583621 )
2017
40
Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets. ( 28821283 )
2017
41
Stereotactic body radiotherapy for lung cancer patients with idiopathic interstitial pneumonias. ( 28919004 )
2017
42
Overlaps and uncertainties of smoking-related idiopathic interstitial pneumonias. ( 29138550 )
2017
43
Postoperative pyothorax a risk factor for acute exacerbation of idiopathic interstitial pneumonia following lung cancer resection. ( 27277761 )
2016
44
Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. ( 26792595 )
2016
45
Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy? ( 27884593 )
2016
46
The pathological features of idiopathic interstitial pneumonia-associated pulmonary adenocarcinomas. ( 27757985 )
2016
47
Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. ( 26792177 )
2016
48
Incidence and prevalence of idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in Korea. ( 27287654 )
2016
49
Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis. ( 27564852 )
2016
50
Idiopathic pleuroparenchymal fibroelastosis - A rare idiopathic interstitial pneumonia. ( 27141432 )
2016

Variations for Idiopathic Interstitial Pneumonia

Expression for Idiopathic Interstitial Pneumonia

Search GEO for disease gene expression data for Idiopathic Interstitial Pneumonia.

Pathways for Idiopathic Interstitial Pneumonia

Pathways related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 CCL2 CXCL8 ELANE ICAM1 IFNG IL13
2
Show member pathways
13.55 CCL2 CCN2 CXCL8 CXCR4 ICAM1 IFNG
3
Show member pathways
13.42 CCL2 CCN2 CXCL8 CXCR4 IL13 IL4
4
Show member pathways
13.41 CCL2 CXCL8 CXCR4 ICAM1 SERPINE1 TGFB1
5
Show member pathways
13.37 CCL2 CXCL8 ICAM1 IFNG IL13 IL4
6
Show member pathways
13.31 CCL2 CCN2 CXCL8 CXCR4 IL13 IL4
7
Show member pathways
13.07 CCL2 CXCL8 CXCR4 ICAM1 TGFB1 VEGFA
8
Show member pathways
13.01 CCL2 CXCL8 IFNG SERPINE1 SFTPA2 SFTPD
9
Show member pathways
12.88 CXCL8 CXCR4 ICAM1 IFNG IL13 IL4
10 12.86 CXCL8 CXCR4 IFNG IL13 IL4 TGFB1
11
Show member pathways
12.81 CCL2 CXCL8 ICAM1 IFNG IL13 IL4
12 12.59 CCL2 CXCR4 IFNG IL4 TLR9
13
Show member pathways
12.36 CCL2 ICAM1 IFNG IL4 SERPINE1
14
Show member pathways
12.36 CCL2 CXCL8 IFNG IL13 IL4 MUC5B
15
Show member pathways
12.29 CCN2 CXCL8 IFNG IL13 IL4 TGFB1
16 12.26 CCN2 GREM1 SERPINE1 TGFB1
17
Show member pathways
12.24 CXCL8 EDN1 MUC5B SERPINE1
18 12.21 IFNG TGFB1 TLR9 VEGFA
19
Show member pathways
12.17 CXCL8 IFNG IL4 SFTPA1 SFTPD TLR9
20 12.12 CCL2 EDN1 ICAM1 IFNG VEGFA
21
Show member pathways
11.98 CCL2 CCN2 CXCL8 ICAM1 IFNG IL13
22 11.97 CXCL8 IFNG SERPINE1 TGFB1
23 11.96 CCL2 CXCL8 ICAM1 IFNG IL4 TGFB1
24 11.94 EDN1 IFNG SERPINE1 VEGFA
25
Show member pathways
11.9 SFTPA1 SFTPA2 SFTPC SFTPD
26 11.88 CXCL8 IFNG TGFB1
27
Show member pathways
11.87 CXCL8 ICAM1 TGFB1
28 11.86 CCL2 CXCL8 ICAM1 IL13 IL4 TGFB1
29 11.85 CCL2 GREM1 TGFB1
30 11.82 CXCL8 ICAM1 IFNG IL13 IL4
31 11.79 IFNG IL13 IL4
32
Show member pathways
11.77 CXCL8 IFNG IL4
33 11.77 CXCL8 SFTPA1 SFTPA2
34 11.75 IFNG TGFB1 TLR9
35 11.75 CCL2 CXCL8 ICAM1 IFNG TGFB1 VEGFA
36 11.73 CXCR4 EDN1 SERPINE1 VEGFA
37 11.71 CCL2 IFNG IL13 IL4 TGFB1
38
Show member pathways
11.7 CXCL8 ICAM1 IFNG VEGFA
39 11.64 IFNG SERPINE1 TGFB1
40 11.58 CXCL8 TGFB1 VEGFA
41 11.54 CCN2 ELANE ICAM1
42
Show member pathways
11.52 SFTPA1 SFTPA2 SFTPD
43 11.52 IFNG IL13 IL4
44 11.52 CCL2 CXCL8 ICAM1 IL13 IL4
45 11.5 CXCL8 ICAM1 IFNG
46
Show member pathways
11.5 SFTPA1 SFTPA2 SFTPC SFTPD
47 11.5 CCL2 CXCL8 EDN1 ICAM1 SERPINE1 TGFB1
48 11.41 EDN1 SERPINE1 VEGFA
49 11.38 ICAM1 IFNG TLR9
50 11.34 IFNG IL13 IL4

GO Terms for Idiopathic Interstitial Pneumonia

Cellular components related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 CCL2 CCN2 CXCL8 EDN1 ELANE GREM1
2 cell surface GO:0009986 9.85 CXCR4 ELANE GREM1 ICAM1 TGFB1 VEGFA
3 collagen trimer GO:0005581 9.63 SFTPA1 SFTPA2 SFTPD
4 rough endoplasmic reticulum GO:0005791 9.61 SFTPA1 SFTPA2 SFTPD
5 platelet alpha granule lumen GO:0031093 9.58 SERPINE1 TGFB1 VEGFA
6 extracellular space GO:0005615 9.58 CCL2 CCN2 CXCL8 EDN1 ELANE GREM1
7 multivesicular body GO:0005771 9.5 SFTPA1 SFTPA2 SFTPD
8 clathrin-coated endocytic vesicle GO:0045334 9.46 SFTPA1 SFTPA2 SFTPC SFTPD
9 lamellar body GO:0042599 9.43 SFTPA1 SFTPA2 SFTPC

Biological processes related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 CCL2 CCN2 ICAM1 TGFB1
2 cellular protein metabolic process GO:0044267 9.98 SFTPA1 SFTPA2 SFTPC SFTPD
3 negative regulation of gene expression GO:0010629 9.97 CCN2 EDN1 IFNG TGFB1 VEGFA
4 positive regulation of protein phosphorylation GO:0001934 9.96 CCN2 IFNG TGFB1 VEGFA
5 response to lipopolysaccharide GO:0032496 9.96 EDN1 ELANE ICAM1 IL13
6 cellular response to lipopolysaccharide GO:0071222 9.95 CCL2 CXCL8 ICAM1 SERPINE1
7 positive regulation of gene expression GO:0010628 9.95 CCN2 IFNG IL13 IL4 TGFB1 TLR9
8 positive regulation of angiogenesis GO:0045766 9.94 CXCL8 GREM1 SERPINE1 VEGFA
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 GREM1 ICAM1 TGFB1 TLR9
10 angiogenesis GO:0001525 9.91 CCL2 CCN2 CXCL8 GREM1 SERPINE1 VEGFA
11 cellular response to tumor necrosis factor GO:0071356 9.9 CCL2 CXCL8 EDN1 ICAM1
12 response to hypoxia GO:0001666 9.89 CXCR4 EDN1 ICAM1 TGFB1 VEGFA
13 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 ICAM1 TGFB1 VEGFA
14 calcium-mediated signaling GO:0019722 9.87 CXCL8 CXCR4 EDN1
15 neutrophil chemotaxis GO:0030593 9.86 CCL2 CXCL8 EDN1
16 positive regulation of cold-induced thermogenesis GO:0120162 9.86 CXCR4 IL13 IL4 VEGFA
17 cellular response to interleukin-1 GO:0071347 9.85 CCL2 CXCL8 EDN1 ICAM1
18 positive regulation of smooth muscle cell proliferation GO:0048661 9.84 EDN1 ELANE IL13
19 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 EDN1 GREM1 TLR9
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.82 EDN1 ICAM1 IFNG
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 IFNG IL13 IL4 VEGFA
22 cytokine-mediated signaling pathway GO:0019221 9.8 CCL2 CXCL8 ICAM1 IL13 IL4 TGFB1
23 positive regulation of B cell proliferation GO:0030890 9.79 IL13 IL4 TLR9
24 positive regulation of phagocytosis GO:0050766 9.79 SFTPA1 SFTPA2 SFTPD
25 positive regulation of MAP kinase activity GO:0043406 9.78 EDN1 ELANE TGFB1 VEGFA
26 response to amino acid GO:0043200 9.77 CCN2 EDN1 ICAM1
27 positive regulation of protein complex assembly GO:0031334 9.74 IFNG TGFB1 VEGFA
28 induction of positive chemotaxis GO:0050930 9.71 CXCL8 VEGFA
29 positive regulation of cardiac muscle cell differentiation GO:2000727 9.71 GREM1 TGFB1
30 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.71 CCL2 TLR9
31 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.71 GREM1 TGFB1 VEGFA
32 macrophage chemotaxis GO:0048246 9.7 CCL2 SFTPD
33 negative regulation of interleukin-17 production GO:0032700 9.7 IFNG TGFB1
34 PERK-mediated unfolded protein response GO:0036499 9.69 CCL2 CXCL8
35 response to molecule of bacterial origin GO:0002237 9.69 CXCL8 TLR9
36 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.68 ELANE TLR9
37 acute inflammatory response to antigenic stimulus GO:0002438 9.68 ELANE ICAM1
38 positive regulation of immunoglobulin production GO:0002639 9.67 IL13 TLR9
39 toll-like receptor signaling pathway GO:0002224 9.67 SFTPA1 SFTPA2 SFTPD TLR9
40 response to salt GO:1902074 9.65 EDN1 TGFB1
41 positive regulation of odontogenesis GO:0042482 9.63 EDN1 TGFB1
42 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.62 GREM1 VEGFA
43 negative regulation of endothelial cell apoptotic process GO:2000352 9.62 ICAM1 IL13 IL4 SERPINE1
44 negative regulation of complement-dependent cytotoxicity GO:1903660 9.58 IL13 IL4
45 surfactant homeostasis GO:0043129 9.46 SFTPA1 SFTPA2 SFTPD VEGFA
46 respiratory gaseous exchange GO:0007585 9.35 EDN1 SFTPA1 SFTPA2 SFTPC SFTPD
47 regulation of signaling receptor activity GO:0010469 9.32 CCL2 CCN2 CXCL8 EDN1 IFNG IL13
48 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 EDN1 GREM1 IL4 SERPINE1 TGFB1 TLR9
49 positive regulation of cell proliferation GO:0008284 10.08 CCN2 EDN1 GREM1 IFNG TGFB1 VEGFA
50 inflammatory response GO:0006954 10 CCL2 CXCL8 CXCR4 IL13 TGFB1 TLR9

Molecular functions related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.62 CCN2 IL4 TGFB1 VEGFA
2 lipopolysaccharide binding GO:0001530 9.43 SFTPA1 SFTPA2 SFTPD
3 vascular endothelial growth factor receptor 2 binding GO:0043184 9.37 GREM1 VEGFA
4 cytokine activity GO:0005125 9.28 CCL2 CXCL8 EDN1 GREM1 IFNG IL13
5 monosaccharide binding GO:0048029 9.13 SFTPA1 SFTPA2 SFTPD
6 protein binding GO:0005515 10.11 CCL2 CCN2 CXCL8 CXCR4 EDN1 ELANE

Sources for Idiopathic Interstitial Pneumonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....